INmune Bio, Inc. (INMB)

Market Cap	97.56M
Revenue (ttm)	42,000
Net Income (ttm)	-41.27M
Shares Out	22.17M
EPS (ttm)	-2.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	287,851
Open	4.360
Previous Close	4.420
Day's Range	4.320 - 4.600
52-Week Range	4.320 - 14.740
Beta	1.78
Analysts	Strong Buy
Price Target	21.00 (+377.27%)
Earnings Date	Oct 31, 2024

About INMB

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2019
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: INMB
• Website: https://www.inmunebio.com

Financial Performance

In 2023, INmune Bio's revenue was $155,000, a decrease of -58.56% compared to the previous year's $374,000. Losses were -$30.01 million, 9.92% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for INMB stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 377.27% from the latest price.

Price Target

$21.0

(377.27% upside)

Analyst Consensus: Strong Buy